Postmenopausal Hormone Therapy and the Risks of Coronary Heart Disease, Breast Cancer, and Stroke

Abstract

The principal findings are briefly reviewed from the Women's Health Initiative (WHI) trials of the most commonly used postmenopausal hormone regimens in the US, conjugated equine estrogens and these same estrogens plus medroxyprogesterone acetate. A more detailed review is presented for three major clinical outcomes: coronary heart disease, the primary trial outcome for which a major benefit was hypothesized; invasive breast cancer, the primary safety outcome for which some adverse effect was expected; and stroke which surfaced as an important adverse effect with both regimens, and one that is influential in decisions concerning the continued use of postmenopausal estrogens alone. The review for these outcomes includes an update on interactions of treatment effects with study subject characteristics and exposures and with pre-randomization biomarker levels. It also includes a focus on timing issues that are important to the understanding of treatment effects. Specifically, with combined estrogen plus progestin coronary heart disease risk was elevated early with the elevation dissipating after a few years of treatment, whereas breast cancer elevations increased during the treatment period, and climbed to about a 3-fold increase following 5 years of adherence. Importantly, breast cancer risk elevations appear to be higher among women who initiate treatment at the menopause, or soon thereafter, compared to women having a longer gap time. Stroke effects, on the other hand didn't seem to vary appreciably with these timing issues. The adverse effect was evidently localized to ischemic strokes, for which there was an approximate 50% increase with either regimen. The rather limited knowledge concerning the biomarkers and biological pathways that mediate the hormone therapy effects on these diseases is also briefly reviewed.

Mitochondrial function in hypoxic ischemic injury and influence of aging

“…Another hormone replacement study showed that treated patients had increased coronary events, strokes, and pulmonary emboli. Consequently, while animal and mechanistic studies have been promising, human trials have demonstrated adverse effects (Prentice, 2014). …”

Blood Serum Atherogenicity: Cellular Test for the Development of Anti- Atherosclerotic Therapy

“…To date, no effective therapy has been established for simultaneous improvement of the quality of life and prevention of atherosclerosis in menopausal women. Hormone replacement therapy turned out to be effective against osteoporosis and in alleviating the menopause symptoms, but, despite the expectations, was unable to lower the risk of atherosclerosis development, as demonstrated by large scale clinical studies [65]. In several documented cases, hormone replacement therapy had oncogenic activity and even stimulated the cardiovascular disorders.…”

Role of Nanotechnology in Epirubicin for Breast Cancer Therapy in Taif City.

“…(38 ) . (39,40) SampledistributionoftheusageofEpirubicinanditsInfluenceintherapy.AlthoughthepercentageofpatientusingEpiru bicinintheirtherapy(43.75%)islessthan who does not use it (56.25%) as shown in table (2-C) Table (3-C) but patients whoinfluence agoodeffectivenessfromEpirubicinHClis78.6%.thepatientswhohaveinappropriate therapy with Epirubicin HCl are only21.4%. The duration of using Epirubicin to give an effective therapy inpatients:-The influence and effectiveness of the medication starts within 3 months of starting treatment, some patients need only to 3 months to show the therapeutic effect ofthe medication they are 18.2 % but the most patients shows the therapeutic effect of the drug in 9 months 54.5 % as table (4-C) shows.…”